Lexicon Pharmaceuticals, Inc. (LXRX) Fair Value 2026

LXRX · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.3 /10

32 fundamental signals · 0 models active

Value Trap Risk

LOW (25/100)

Quick Summary — As of 2026-08-28, Lexicon Pharmaceuticals, Inc. (LXRX) trades at $2.29. QOC: 6.3/10. Value Trap Risk: 25/100 (LOW). 0/13 models active.

Key Facts

Ticker
LXRX
Price
$2.29
Quality Score
6.3/10
Value Trap Risk
25/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Limited model coverage (0/13) may reduce confidence

What Fair Value Does Each Model Give LXRX?

0 Intrinsic Value Models vs. Current Price ($2.29)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is Lexicon Pharmaceuticals, Inc. (LXRX) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Lexicon Pharmaceuticals, Inc. currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About LXRX?

0 of 13 models are currently active for LXRX. See which stocks rank higher →

How Does LXRX Rank in Biotechnology?

Among 625 Biotechnology stocks, LXRX ranks #119 by Quality of Company score. CirclFi's QOC score of 6.3/10 evaluates 32 fundamental signals. A score of 6.3 indicates above-average quality.

See all Most Undervalued Biotechnology Stocks →

The Biotechnology sector introduces analytical considerations specific to life sciences company businesses. For Lexicon Pharmaceuticals, Inc., metrics like market exclusivity window provide important context that general-purpose valuation models may underweight.

Is LXRX a Value Trap?

CirclFi's Value Trap algorithm assigns LXRX a score of 25/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for Lexicon Pharmaceuticals, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, Lexicon Pharmaceuticals, Inc. scores 6.3 out of 10 on our 32-signal quality assessment, a solid rating that maintains reasonable quality metrics with some areas for improvement. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every LXRX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Lexicon Pharmaceuticals, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

PHATPhathom Pharmaceuticals, Inc.QOC 6.3NTLAIntellia Therapeutics, Inc.QOC 6.3ORMPOramed Pharmaceuticals Inc.QOC 6.3XFORX4 Pharmaceuticals, Inc.QOC 6.3BRTXBioRestorative Therapies, Inc.QOC 6.3EVMNEvommune, Inc.QOC 6.2CALCCalciMedica, Inc.QOC 5.1SIONSionna Therapeutics, Inc.QOC 4.6SIGYSigyn Therapeutics, Inc.QOC 3.4EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: PHAT · NTLA · ORMP · XFOR · BRTX · EVMN · CALC · SION · SIGY · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to LXRX?

6 companies across all industries closest to LXRX’s Quality of Company score of 6.3/10.

CNTYCentury Casinos, Inc.QOC 6.3SLGSL Green Realty Corp.QOC 6.3NHTCNatural Health Trends Corp.QOC 6.3AERGApplied Energetics, Inc.QOC 6.3UAMYUnited States Antimony CorporationQOC 6.3NVDANVIDIA CorporationQOC 10.0

Read investment analysis: CNTY · SLG · NHTC · AERG · UAMY · NVDA

Where Does LXRX Sit in CirclFi's Biotechnology Rankings?

LXRX is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Lexicon Pharmaceuticals, Inc.’s Valuation?

What is Lexicon Pharmaceuticals, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Lexicon Pharmaceuticals, Inc. (LXRX). The Quality of Company score is 6.3/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is LXRX overvalued or undervalued right now?

At $2.29, 0 of 0 active models suggest LXRX may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Lexicon Pharmaceuticals, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 6.3 mean for LXRX?

Lexicon Pharmaceuticals, Inc.'s QOC of 6.3/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on LXRX?

CirclFi analyzes LXRX with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is LXRX a value trap in 2026?

Lexicon Pharmaceuticals, Inc.'s Value Trap score is 25/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Lexicon Pharmaceuticals, Inc. (LXRX) a Quality of Company score of 6.3/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/LXRX/ · Methodology
Primary sources for this LXRX valuation
  • Financial statements: Lexicon Pharmaceuticals, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001062822) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for LXRX as of ; valuations recomputed .